Tatva Chintan Pharma Chem Ltd. stands out as a sector laggard due to its weak growth metrics and high valuation ratios relative to its peers. The company exhibits declining revenue and EPS, alongside high PE and PEG ratios, suggesting it is overvalued given its performance. In contrast, peers like Pidilite Industries and SRF show strong growth and profitability, indicating a more favorable investment profile.

• • Tatva Chintan shows negative revenue growth, -2.74% YoY, and declining EPS over 3 years.
• • High PE ratio of 622.20 indicates overvaluation, with peers averaging significantly lower values.
• • Strong performers like Pidilite Industries and SRF demonstrate solid revenue growth and lower valuation metrics.